Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Affron (Saffron)

Pharmactive, standardized saffron extract

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Dietary ingredient (not FDA-evaluated for efficacy)

Reference only. Not medical advice.

What can go wrong

Saffron is generally safe at supplement doses; high doses can cause GI effects. It does not raise testosterone.

This is something to take to a clinician. The Atlas can tell you what is known about affron (saffron) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Affron is a Pharmactive-branded saffron (Crocus sativus) extract standardized for Lepticrosalides, with human trials for mood and some sexual-function endpoints. It is included in some men's formulas, but it is best understood as a mood/libido ingredient rather than a testosterone booster, saffron's evidence is for affect and sexual satisfaction, not serum testosterone.

A mood/libido extract, not a testosterone booster.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Mood; sexual satisfaction (not testosterone)

What people get wrong

  • Often saidSaffron boosts testosterone

    ActuallySaffron's human evidence is for mood and sexual function, not serum testosterone, a libido/affect ingredient, not a T-booster.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Supplier
Pharmactive
Standardization
Lepticrosalides (saffron actives)
Evidence
Mood, sexual function (not T)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Affron (Saffron). A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.